HSBC initiated coverage on Agilent Technologies with a "Buy" rating. The bank set a price target of $180.00. This target implies a potential 29% upside.
HSBC referred to Agilent as a "quality growth" company. Agilent maintains 5-7% medium-term growth guidance. This contrasts with peers who have lowered their forecasts.
Analysts believe Agilent is well-positioned for sustained earnings growth. Key drivers include the lab equipment replacement cycle and growth in the contract development and manufacturing (CDMO) business.
Margin recovery from the "Ignite" program also contributes. Improving biotech sector sentiment supports a strong outlook for 2026-2027.